BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is continuing preparations for the Phase 3b ENDURANCE trial of NurOwn ® for the treatment of patients with amyotrophic lateral sclerosis (ALS). In May ...

Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

On July 3, 2025, a Citizen’s Petition was filed with the U.S. Food and Drug Administration in which the petitioners, a group consisting mostly of amyotrophic lateral sclerosis (ALS) patients who have ...

Receives Regulatory Clearance to Initiate Phase 3b Trial of NurOwn ® in ALS On May 19, 2025, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced that the U.S. Food and Drug Administration (FDA) ...

Fintel reports that on July 11, 2024, Maxim Group upgraded their outlook for Brainstorm Cell Therapeutics (NasdaqCM:BCLI) from Hold to Buy. As of July 4, 2024, the average one-year price target for ...

Brainstorm Cell Therapeutics Inc., a biotechnology company, is dedicated to the development and commercialization of autologous cell therapies for the treatment of neurodegenerative diseases. The ...